Buscar resultados de ensayos clínicos
Coagulation Protein Disorders - 25 Studies Found
Estado | Estudiar |
Completed |
Nombre del estudio: Epidemiology and Immunology of Hemophilia A Inhibitors Condición:
Fecha: 2000-05-25 |
Completed |
Nombre del estudio: Evaluation of the Reasons and Consequences of Bleeding in Late Teens and Early Adulthood Patients With Severe Hemophilia A Condición:
Fecha: 2008-10-29 Intervenciones:
|
Completed |
Nombre del estudio: Cooperative Study of Factor VIII Inhibitors Condición:
|
Not yet recruiting |
Nombre del estudio: Bleeding Risk Evaluation in Haemophilia Patients Under Antiplatelet Therapies Condición: Hemophilia Fecha: 2017-05-16 Intervenciones: Other: Non interventionnal study A query form to all concerned patients by each investigating centre wil |
Available |
Nombre del estudio: An Expanded Access Program of Emicizumab in Participants With Hemophilia A With Inhibitors Condición: Hemophilia A Fecha: 2017-05-12 Intervenciones: Biological: Emicizumab Participants will receive emicizumab at a loading dose of 3 milligrams per kilogr |
Not yet recruiting |
Nombre del estudio: DDAVP vs. Exercise Condición: Children With Mild Hemophilia A Fecha: 2017-04-27 Intervenciones:
|
Not yet recruiting |
Nombre del estudio: Study of rFVIIIFc for ITI in Haemophilia A Patients With Inhibitors Who Have Failed Previous ITI Therapies Condición: Hemophilia A Fecha: 2017-03-31 Intervenciones: Biological: Recombinant coagulation factor (rFVIIIFc) rFVI |
Recruiting |
Nombre del estudio: Alphanate in Immune Tolerance Induction Therapy Condición: Hemophilia A, Congenital Fecha: 2017-03-23 Intervenciones: Biological: Alphanate Daily intravenous infusion of Alphanate 100 IU/kg/day |
Not yet recruiting |
Nombre del estudio: A Study to Evaluate Efficacy of rFVIIIFc for Immune Tolerance Induction (ITI) in Severe Hemophilia A Participants With Inhibitors Undergoing the First ITI Treatment Condición: Hemophilia A Fecha: 2017-03-10 Intervenciones: Biological: rFVIIIFc rFVIIIFc 200 IU/kg/day in ITI Period and 50 or 100 IU/kg (adjusted according to Inv |
Recruiting |
Nombre del estudio: Study Comparing the Pharmacokinetic of Biosimilar Eptacog Alfa With Novoseven®, in Patients With Congenital Factor VII Deficiency Condición: Factor VII Deficiency Fecha: 2017-03-04 Intervenciones:
|